Innovating Works

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Activa
Mostrando 1 al 20 de 143 resultados
LIFETIME: Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ on Ch... "Understanding cancer metabolism at the individual patient level is central to making accurate early-stage diagnoses and providing effective...
2024-10-21 - 2030-02-28 | Financiado
VIDA: VHIO International postDoctoral programme for translAtional research FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON tramitó un HORIZON EUROPE: The proposed VHIO International postDoctoral programme for translAtional research (VIDA) aims at enabling outstanding junior scientists of a...
2024-09-12 - 2029-12-31 | Financiado
OrthoBots: Therapeutic Effect of Nanobots in the Treatment of Joint Diseases FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: Arthritis, a widespread inflammatory condition, affecting millions globally, necessitates urgent advancements in therapeutic approaches. Pre...
2024-07-23 - 2026-04-30 | Financiado
SPM4.0: Autonomous Scanning Probe Microscopy for Life Sciences and Medicine powered by Artificial Intelligen... Artificial Intelligence is pushing forward the Industrial Revolution 4.0, which is transforming many areas of Society, including Science and...
2024-07-05 - 2028-10-31 | Financiado
UNLOOC: Unlocking data content of Organ On Chips The launch of a novel drug to the market is preceded by clinical testing and validation both on animal in vitro and in vivo models. Animal m...
2024-06-28 - 2027-04-30 | Financiado
ENTRY-DM: Interdisciplinary doctoral training on oligonucleotide based therapies for myotonic dystrophy Rare diseases, though individually infrequent, collectively pose important challenges for patients, clinicians and researchers in terms of d...
2024-06-28 - 2029-02-28 | Financiado
GLAM-Map: Global Amyloid Mapping Solving Amyloid Nucleation by Deep Mutagenesis FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: ERC-2023-COG Amyloid fibrils form and precipitate in more than 50 incurable human diseases, including Alzheimer’s and Parkinson’s disease. All proteins m...
2024-02-14 - 2029-04-30 | Financiado
SpaceClones: Integrative profiling and engineering of clonal cancer cell behaviours from the tissue level down t... FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: ERC-2023-STG Clonal evolution in tumours, the process by which cancer cells expand, diversify and are selected, is a major determinant of tumour growth a...
2023-11-15 - 2028-12-31 | Financiado
PHOTOTHERAPORT: LUMINESCENT IMPLANTS AS PORTS FOR LIGHT BASED THERAPIES FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: HORIZON-EIC-2023-PATHFINDEROPEN-01 A major difficulty in developing clinically useful treatments is to deliver therapeutic action with spatiotemporal precision and pharmacolog...
2023-10-31 - 2026-12-31 | Financiado
MucOncoBots: Drug loaded nanobots for transmucosal delivery to mucinous tumours FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: ERC-2023-POC Mucus is a defensive barrier that protects the underlying cells from pathogens and toxic compounds, although it also hinders the delivery of...
2023-09-25 - 2025-03-31 | Financiado
MAIN: Metabolic anti inflammatory nanomedicines FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: ERC-2023-POC Our proposal is to create new nanomedicines for identifying anti-inflammatory therapies. Through the optimisation of synthetic procedures, w...
2023-08-03 - 2025-03-31 | Financiado
MicroHyperProbe: Hyperpolarized sensors for probing metabolism in microfluidic organ on chip platforms FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Hyperpolarized (HP) magnetic resonance imaging has emerged as a promising method for probing the biological characteristics of living tissue...
2022-08-02 - 2025-03-15 | Financiado
BEndTarG: Brain Endothelium TARgeted Gene therapy to improve A clearance in Alzheimer s Disease FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Alzheimer disease (AD) is the most common cause of dementia (60-80% of cases) with a prevalence near 50 million people. There is no cure ava...
2022-07-19 - 2024-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.